ConductScience.org, home

Trial · NCT03205150

Results by group30

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change From Baseline in Alanine Aminotransferase (ALT) at Week 12LIK066 30 mg-22.06Standard Error 4.16Units per Liter (U/L)
Change From Baseline in Alanine Aminotransferase (ALT) at Week 12LIK066 150 mg-30.41Standard Error 4.52Units per Liter (U/L)
Change From Baseline in Alanine Aminotransferase (ALT) at Week 12Placebo-8.77Standard Error 5.99Units per Liter (U/L)
Change From Baseline in Percent Liver Fat at Week 12LIK066 30 mg-4.40Standard Error 0.81Percentage of Liver Fat
Change From Baseline in Percent Liver Fat at Week 12LIK066 150 mg-6.92Standard Error 0.87Percentage of Liver Fat
Change From Baseline in Percent Liver Fat at Week 12Placebo-2.67Standard Error 1.17Percentage of Liver Fat
Percent Change From Baseline in Total Body Weight at Week 12LIK066 30 mg-3.48Standard Error 0.47percentage change
Percent Change From Baseline in Total Body Weight at Week 12LIK066 150 mg-4.51Standard Error 0.52percentage change
Percent Change From Baseline in Total Body Weight at Week 12Placebo-0.33Standard Error 0.68percentage change
Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Week 12LIK066 30 mg-0.2Standard Deviation 0.65scores on a scale
Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Week 12LIK066 150 mg-0.1Standard Deviation 0.61scores on a scale
Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Week 12Placebo0.1Standard Deviation 0.37scores on a scale
Change From Baseline in the Concentration of Hyaluronic Acid at Week 12.LIK066 30 mg-3.4Standard Deviation 75.38ug/L
Change From Baseline in the Concentration of Hyaluronic Acid at Week 12.LIK066 150 mg0.4Standard Deviation 30.56ug/L
Change From Baseline in the Concentration of Hyaluronic Acid at Week 12.Placebo4.7Standard Deviation 21.73ug/L
Change From Baseline in the Concentration of Procollagen Type Iii N-Terminal Peptide (PIIINP) at Week 12.LIK066 30 mg-1.7Standard Deviation 2.73ug/L
Change From Baseline in the Concentration of Procollagen Type Iii N-Terminal Peptide (PIIINP) at Week 12.LIK066 150 mg-1.2Standard Deviation 3.66ug/L
Change From Baseline in the Concentration of Procollagen Type Iii N-Terminal Peptide (PIIINP) at Week 12.Placebo0.3Standard Deviation 1.88ug/L
Change From Baseline in the Concentration of Tissue Inhibitor Of Metalloproteinase 1 (TIMP-1) at Week 12.LIK066 30 mg-3.0Standard Deviation 38.98ug/L
Change From Baseline in the Concentration of Tissue Inhibitor Of Metalloproteinase 1 (TIMP-1) at Week 12.LIK066 150 mg-10.9Standard Deviation 38.21ug/L

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03205150/results